M2 TEACHING UNDERSTANDING PHARMACOLOGY

Similar documents
Antihypertensive drugs SUMMARY Made by: Lama Shatat

Antihypertensive Agents Part-2. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

Heart failure. Failure? blood supply insufficient for body needs. CHF = congestive heart failure. increased blood volume, interstitial fluid

LXIV: DRUGS: 4. RAS BLOCKADE

HYPERTENSION: Sustained elevation of arterial blood pressure above normal o Systolic 140 mm Hg and/or o Diastolic 90 mm Hg

HEART FAILURE PHARMACOLOGY. University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D

Heart Failure (HF) Treatment

Introductory Clinical Pharmacology Chapter 41 Antihypertensive Drugs

Cardiovascular Pharmacotherapy

The Failing Heart in Primary Care

Heart Failure. Subjective SOB (shortness of breath) Peripheral edema. Orthopnea (2-3 pillows) PND (paroxysmal nocturnal dyspnea)

Towards a Greater Understanding of Cardiac Medications Foundational Cardiac Concepts That Must Be Understood:

Cardiac Drugs: Chapter 9 Worksheet Cardiac Agents. 1. drugs affect the rate of the heart and can either increase its rate or decrease its rate.

Definition of Congestive Heart Failure

HYPERTENSION IN CKD. LEENA ONGAJYOOTH, M.D., Dr.med RENAL UNIT SIRIRAJ HOSPITAL

7/7/ CHD/MI LVH and LV dysfunction Dysrrhythmias Stroke PVD Renal insufficiency and failure Retinopathy. Normal <120 Prehypertension

Chapter 23. Media Directory. Cardiovascular Disease (CVD) Hypertension: Classified into Three Categories

Beta 1 Beta blockers A - Propranolol,

Estimated 5.7 million Americans with HF. 915, 000 new HF cases annually, HF incidence approaches

Management of Hypertension

Disclosure Statement. Heart Failure: Refreshers and Updates. Objectives. CHF: Chronic Heart Failure. Definitions. Definitions 2/19/2018

Diabetic Nephropathy 2009

Pathophysiology: Heart Failure

DRUG CLASSES BETA-ADRENOCEPTOR ANTAGONISTS (BETA-BLOCKERS)

Antihypertensives. Antihypertensive Classes. RAAS Inhibitors. Renin-Angiotensin Cascade. Angiotensin Receptors. Approaches to Hypertension Treatment

Chapter 10 Worksheet Blood Pressure and Antithrombotic Agents

ANGIOTENSIN II RECEPTOR BLOCKERS: MORE THAN THE ALTERNATIVE PRESENTATION BY: PATRICK HO, USC PHARM D. CANDIDATE OF 2017 MENTOR: DR.

1. Despite the plethora of new ACE-inhibitors they offer little advantage over the earlier products captopril and enalapril.

MEDICAL MANAGEMENT OF PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION

Outline. Pathophysiology: Heart Failure. Heart Failure. Heart Failure: Definitions. Etiologies. Etiologies

Peripartum Cardiomyopathy. Lavanya Rai Manipal

Cardiac Output MCQ. Professor of Cardiovascular Physiology. Cairo University 2007

Circulation. Blood Pressure and Antihypertensive Medications. Venous Return. Arterial flow. Regulation of Cardiac Output.

Antihypertensives. Diagnostic category

Management of Hypertension. M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine

Introduction. Factors affecting blood pressure: 1-COP = HR X SV mainly affect SBP. 2-TPR = diameter of arterioles X viscosity of blood affect DBP

Improving Transition of Care in Congestive Heart Failure. Mark J. Gloth, DO, MBA. Vice President, Chief Medical Officer HCR ManorCare

Byvalson. (nebivolol, valsartan) New Product Slideshow

Heart Failure. Dr. William Vosik. January, 2012

Section 3, Lecture 2

1. Antihypertensive agents 2. Vasodilators & treatment of angina 3. Drugs used in heart failure 4. Drugs used in arrhythmias

Invokana (canagliflozin) NEW INDICATION REVIEW

신장환자의혈압조절 나기영. Factors involved in the regulation of blood pressure

Hypertension. Penny Mosley MRPharmS

VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005

Heart Failure. Dr. Alia Shatanawi

CONGESTIVE CARDIAC FAILURE. Dr.T.Rajathilagam, M.D., S.R.M. Medical College

Chronic heart failure: management of chronic heart failure in adults in primary and secondary care (partial update)

Hypertension CHAPTER-I CARDIOVASCULAR SYSTEM. Dr. K T NAIK Pharm.D Associate Professor Department of Pharm.D Krishna Teja Pharmacy College, Tirupati

CKD Satellite Symposium

Medical Treatment for acute Decompensated Heart Failure. Vlasis Ninios Cardiologist St. Luke s s Hospital Thessaloniki 2011

Pharmacologic Management of Hypertension

Difficult to Treat Hypertension

DRUGS USED TO TREAT HYPERTENSION BY ALI ALALAWI

Incidence. 4.8 million in the United States. 400,000 new cases/year. 20 million patients with asymptomatic LV dysfunction

Optimal blockade of the Renin- Angiotensin-Aldosterone. in chronic heart failure

Chapter 10. Learning Objectives. Learning Objectives 9/11/2012. Congestive Heart Failure

DIAGNOSIS AND MANAGEMENT OF ACUTE HEART FAILURE

Cardiorenal and Renocardiac Syndrome

HEART FAILURE. Heart Failure in the US. Heart Failure (HF) 3/2/2014

Dr Doris M. W Kinuthia

Heart Failure Treatments

Topic Page: congestive heart failure

Nora Goldschlager, M.D. SFGH Division of Cardiology UCSF

ANTI- HYPERTENSIVE AGENTS

Hypertension in Aortic Valve Disease

Index. Note: Page numbers of article titles are in boldface type.

Summary/Key Points Introduction

Cardiac Pathophysiology

β adrenergic blockade, a renal perspective Prof S O McLigeyo

Hypertension Update. Objectives 4/28/2015. Beverly J. Mathis, D.O. OOA May 2015

Akash Ghai MD, FACC February 27, No Disclosures

Heart Failure. Cardiac Anatomy. Functions of the Heart. Cardiac Cycle/Hemodynamics. Determinants of Cardiac Output. Cardiac Output

Heart Failure Clinician Guide JANUARY 2018

Hypertensives Emergency and Urgency

Going to high altitude with heart disease. Prof. Dr. med. Stefano Rimoldi High Altitude Medicine Inselspital Bern

A Guide to the Etiology, Pathophysiology, Diagnosis, and Treatment of Heart Failure. Part I: Etiology and Pathophysiology of Heart Failure

keyword: diuretics Drug monitoring Monitoring diuretics in primary care 2 March 2009 best tests

Combining Antihypertensives in People with Diabetes

Pathophysiology: Heart Failure. Objectives

Cardiovascular Protection and the RAS

Hypertension Management Focus on new RAAS blocker. Disclosure

Stages of Chronic Kidney Disease (CKD)

Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease

Systemic Hypertension Dr ahmed almutairi Assistant professor Internal medicine dept

Elements for a public summary

Chapter (9) Calcium Antagonists

hypertension Head of prevention and control of CVD disease office Ministry of heath

Drugs Used in Heart Failure. Assistant Prof. Dr. Najlaa Saadi PhD pharmacology Faculty of Pharmacy University of Philadelphia

Cardiovascular Clinical Practice Guideline Pilot Implementation

Heart Failure Pharmacotherapy An Update

Heart Failure CTSHP Fall Seminar

5.2 Key priorities for implementation

Combination of renin-angiotensinaldosterone. how to choose?

HTN of pregnancy is serious and must be controlled, because without monitoring it can develop into pre-eclampsia and finally to eclampsia.

Pre-discussion questions

sympatholytics sympatholytics sympatholytics

Treatment of T Angina reatment of By Ali Alalawi

1/4/18. Heart Failure Guideline Review and Update. Disclosure. Pharmacist Objectives. Pharmacy Technician Objectives. What is Heart Failure?

Younger adults with a family history of premature artherosclerotic disease should have their cardiovascular risk factors measured.

Transcription:

M2 TEACHING UNDERSTANDING PHARMACOLOGY USING CVS SYSTEM AS AN EXAMPLE NIGEL FONG 2 JAN 2014

TODAY S OBJECTIVE Pharmacology often seems like an endless list of mechanisms and side effects to memorize. To realise that a drug s effects and side effects may largely be understood by exploring its mechanism in relation to physiology and pathophysiology To integrate physiology, pathology, pharmacology, and clinical exam. To illustrate the advice of understand not memorize and think of a patient Key goal is not to teach content, but to teach an approach you can apply to all other systems.

TODAY S TOPICS Will cover: Drugs used in heart failure Drugs used in hypertension Drugs used in diabetes Also important in CVS drugs but not taught to you yet: Anti-platelet agents and anticoagulants.

APPROACH Understand the disease s natural history and impact, and hence the GOALS of treatment ( Why ) What is symptomatic treatment and when do we use it? Understand the disease pathophysiology and hence the PRINCIPLES of treatment ( What ) Understand the pharmacological mechanisms used to achieve the goals, and hence the logical effects, side effects, contraindications, and drug interactions. Fill in the remaining idiosyncratic effects and side effects (these do not logically follow from its mechanism) Address not only the disease itself, but also its complications and potential complications intervene early if indicated

HEART FAILURE Case: Chronic heart failure - systolic dysfunction due to old infarct Natural history & impact Symptoms of heart failure can be debilitating e.g. dyspnoea Heart failure progresses (Why?) Risk of re-infarct (Why?) Principles of management: Symptom control: dyspnoea, orthorpnoea etc Retarding disease progression Preventing re-infarct: investigate and treat the underlying cause of heart failure

HEART FAILURE Its clinical presentation directly follows from its pathophysiology: Consider Left Heart Failure (simplified schema) Old infarct Valve regurgitation Aortic Hypertension stenosis Contractility Preload Afterload Forward failure tissue hypoperfusion Cardiac Output RAAS activation, fluid retention Myocardial remodelling Backward failure congestion in Lungs, Liver, Peripheries Right heart failure

HEART FAILURE Understand PRINCIPLES of treatment: inhibit the vicious cycle that causes heart failure to progressively worsen. Old infarct Valve regurgitation Aortic Hypertension stenosis Contractility Preload Afterload Forward failure tissue hypoperfusion Cardiac Output RAAS activation, fluid retention Myocardial remodelling Backward failure congestion in Lungs, Liver, Peripheries Right heart failure

HEART FAILURE Inhibits fluid retention: improves symptoms, inhibits remodelling with evidence-based survival benefit ACE-I or ARB Aldosterone antagonists Inhibits remodelling: proven survival benefit Beta-blockers: some (not all) are evidence-based. Improves symptoms but NO survival benefit Diuretics: improve symptoms by reducing fluid overload Digoxin: improves symptoms and reduces readmissions Inotropes: in intractable cases

HEART FAILURE Treating the underlying cause: In this case ischemic heart disease Anti-platelets Risk factor control: lipids, BP, and blood sugars Revascularization Notes & reminders: Management has to be tailored to the patient. Not all heart failure is equal, not always due to old infarct. Not all management is pharmacological Must also look out for and manage complications (of disease and of treatment)

HEART FAILURE 70-year old patient is started on Enalapril and frusemide. How do you expect him to benefit What do you have to monitor? What if: Now comes in with palpitations Has chronic cough for 2 months Complains of giddiness, especially on waking up. Poor urine output and serum creatinine rises. 6 months later - Elevated JVP, basal crepitations, lower limb edema

HEART FAILURE Understand physiological role of ACE: Physiological response to hypovolemia. Heart failure is perceived as a state of relative hypovolemia (why?) RAAS axis: Angiotensin-II & Aldosterone production Fluid excretion: glomerular arteriole dilation (angiotensin II) and Na reabsorption (aldosterone) Sympathetic stimulation (angiotensin II) causing vasoconstriction

HEART FAILURE ACE - I Bradykinin breakdown Angiotensin-II Aldosterone Cough Systemic Vasodilation Glom arteriole vasodilation Na reabsorption K secretion Hypotension Beneficial in hypertension Acute renal failure if bilateral renal artery stenosis Fluid retention Hyperkalemia Also: teratogenic Improve symptoms Inhibit remodelling

HEART FAILURE Patient is started on Enalapril and frusemide. How do you expect him to benefit What do you have to monitor? What if: Now comes in with palpitations Has chronic cough for 2 months Complains of giddiness, especially on waking up. Poor urine output and serum creatinine rises.

APPROACH Understand the disease s natural history and impact, and hence the GOALS of treatment ( Why ) What is symptomatic treatment and when do we use it? Understand the disease pathophysiology and hence the PRINCIPLES of treatment ( What ) Understand the pharmacological mechanisms used to achieve the goals, and hence the logical effects, side effects, contraindications, and drug interactions. Fill in the remaining idiosyncratic effects and side effects (these do not logically follow from its mechanism) Address not only the disease itself, but also its complications and potential complications intervene early if indicated

ESSENTIAL HYPERTENSION Natural history & impact Usually asymptomatic but long term danger Heart hypertrophy predisposing to MI or heart failure Brain stroke Kidney glomerulosclerosis, proteinuria Principles of management: Ask Is there really hypertension Nonpharmacological diet, salt restriction, exercise, etc. Pharmacological Control other cardiovascular risk factors

ESSENTIAL HYPERTENSION Therapeutic options: A: ACE-I or ARB B: Beta-blocker C: Ca-channel blocker D: Diuretics Notes: BP drugs are synergistic, usually >1 required Achieving target BP more important than specific drug used. Hence, presence of comorbids is used to choose the BP drug. Malignant hypertension and hypertension in pregnancy are separate entities

ESSENTIAL HYPERTENSION α 1 Beta-blocker β 1 β 2 Beta-blockers differ in their selectivity α 2 VESSELS Vasodilation HEART -ve inotropic -ve chronotropic KIDNEY renin BRONCHIOLES Vasoconstriction METABOLIC sympathetic response to hypoglycemia Bradycardia angina, remodelling in heart failure BP reduction Exacerbate asthma Hypoglycemia danger in DM Also: fatigue, bad dreams

ESSENTIAL HYPERTENSION Choice of anti-hypertensive agent based on comorbidity: Asthma ACE-I Beta-blocker CCB Diuretic DM proteinuria Hypo danger Glucose CCF remodelling Exacerbates remodelling May worsen severe CCF Non-DHP may worsen Angina O 2 demand O 2 demand Pregnancy Teratogen Careful Arrhythmia Gout Helps tachys Worsen blocks Relieves symptoms May worsen K Will K K-losing help K-sparing K

ESSENTIAL HYPERTENSION Choice of anti-hypertensive agent based on comorbidity: Asthma ACE-I Beta-blocker CCB Diuretic DM proteinuria Hypo danger Glucose CCF remodelling Exacerbates remodelling May worsen severe CCF Non-DHP may worsen Angina O 2 demand O 2 demand Pregnancy Teratogen Careful Arrhythmia Gout Helps tachys Worsen blocks Relieves symptoms May worsen K Will K K-losing help K-sparing K

DIABETES Goal: Good glycemic control, prevent downstream complications. Acute Chronic Hypoglycemia Diabetic ketoacidosis Microvascular Macrovascular Balance vs hypo risk Principles: Nephropathy Neuropathy Retinopathy Peripheral Vascular disease Type 1: absolute insulin insufficiency, absolute replacement. Type 2: natural history is progressive beta cell failure. Cerebrovascular disease Ischemic Heart disease

DIABETES Key thrusts of pharmacological management of DM: Increase sensitivity to insulin (metformin). - Works when beta cells are intact - Unlikely effective in T1DM, or late T2DM Increase amount of insulin - Increase endogenous secretion (secretagogues) - Give exogenous insulin Why are there so many different types of insulin?

DIABETES Having different insulins allow us to choose different dosing regimens Source http://sketchymedicine.com/ http://dtc.ucsf.edu/types-of-diabetes/type1/treatment- of-type-1-diabetes/medications-and-therapies/type-1- insulin-therapy/types-of-insulin/

SUMMARY Understand the disease s natural history and impact, and hence the GOALS of treatment ( Why ) What is symptomatic treatment and when do we use it? Understand the disease pathophysiology and hence the PRINCIPLES of treatment ( What ) Understand the pharmacological mechanisms used to achieve the goals, and hence the logical effects, side effects, contraindications, and drug interactions. Fill in the remaining idiosyncratic effects and side effects (these do not logically follow from its mechanism) Address not only the disease itself, but also its complications and potential complications intervene early if indicated